A point mutation in the gamma(2) subunit of gamma-aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity

被引:90
作者
Buhr, A [1 ]
Sigel, E [1 ]
机构
[1] UNIV BERN, DEPT PHARMACOL, CH-3010 BERN, SWITZERLAND
关键词
D O I
10.1073/pnas.94.16.8824
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Benzodiazepines allosterically modulate gamma-aminobutyric acid (GABA) evoked chloride currents of gamma-aminobutyric acid type A (GABA(A)) receptors, Coexpression of either rat gamma(2) or gamma(3), in combination with alpha(1) and beta(2) subunits, results both in receptors displaying high [H-3]Ro 15-1788 affinity, However, receptors containing a gamma 3 subunit display a 178-fold reduced affinity to zolpidem as compared with gamma(2)-containing receptors. Eight chimeras between gamma(2) and gamma(3) were constructed followed by nine different point mutations in gamma(2), each to the homologous amino acid residue found in gamma(3). Chimeric or mutant gamma subunits were coexpressed with alpha(1) and beta(2) in human embryonic kidney 293 cells to localize amino acid residues responsible for the reduced zolpidem affinity, Substitution of a methionine-to-leucine at position 130 of gamma(2) (gamma(2)M130L) resulted in a 51-fold reduction in zolpidem affinity whereas the affinity to [H-3]Ro 15-1788 remained unchanged, The affinity for diazepam was only decreased by about 2-fold, The saute mutation resulted in a 9-fold increase in Cl 213572 affinity, A second mutation (gamma(2)M57I) was found to reduce zolpidem affinity by about 4-fold. Wild-type and gamma(2)M130L-containing receptors were functionally expressed in Xenopus oocytes. Upon mutation allosteric coupling between agonist and modulatory sites is preserved, Dose-response curves for zolpidem and for diazepam showed that I-he zolpidem but not the diazepam apparent affinity is drastically reduced, The apparent GABA affinity is not significantly affected by the gamma(2)M130L mutation, The identified amino acid residues may define part of the benzodiazepine binding pocket of GABA(A) receptors. As the modulatory site in the GABA(A) receptor is homologous to the GABA site, and to all agonist sites of related receptors, gamma(2)M130 may either point to a homologous region important for agonist binding in all receptors or define a new region not underlying this principle.
引用
收藏
页码:8824 / 8829
页数:6
相关论文
共 37 条
[21]   GABA(A) RECEPTOR CHANNELS [J].
MACDONALD, RL ;
OLSEN, RW .
ANNUAL REVIEW OF NEUROSCIENCE, 1994, 17 :569-602
[22]  
MALHERBE P, 1990, J NEUROSCI, V10, P2330
[23]   GABA-A-RECEPTOR EXPRESSED FROM RAT-BRAIN ALPHA-SUBUNIT AND BETA-SUBUNIT CDNAS DISPLAYS POTENTIATION BY BENZODIAZEPINE RECEPTOR LIGANDS [J].
MALHERBE, P ;
DRAGUHN, A ;
MULTHAUP, G ;
BEYREUTHER, K ;
MOHLER, H .
MOLECULAR BRAIN RESEARCH, 1990, 8 (03) :199-208
[24]  
MIHIC SJ, 1994, J BIOL CHEM, V269, P32768
[25]   GAMMA-AMINOBUTYRIC ACIDA RECEPTOR ALPHA-5-SUBUNIT CREATES NOVEL TYPE-II BENZODIAZEPINE RECEPTOR PHARMACOLOGY [J].
PRITCHETT, DB ;
SEEBURG, PH .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (05) :1802-1804
[26]   GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR POINT MUTATION INCREASES THE AFFINITY OF COMPOUNDS FOR THE BENZODIAZEPINE SITE [J].
PRITCHETT, DB ;
SEEBURG, PH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (04) :1421-1425
[27]   IMPORTANCE OF A NOVEL GABAA RECEPTOR SUBUNIT FOR BENZODIAZEPINE PHARMACOLOGY [J].
PRITCHETT, DB ;
SONTHEIMER, H ;
SHIVERS, BD ;
YMER, S ;
KETTENMANN, H ;
SCHOFIELD, PR ;
SEEBURG, PH .
NATURE, 1989, 338 (6216) :582-585
[28]   FROM ION CURRENTS TO GENOMIC ANALYSIS - RECENT ADVANCES IN GABA(A) RECEPTOR RESEARCH [J].
RABOW, LE ;
RUSSEK, SJ ;
FARB, DH .
SYNAPSE, 1995, 21 (03) :189-274
[29]   SEQUENCE AND FUNCTIONAL EXPRESSION OF THE GABA-A RECEPTOR SHOWS A LIGAND-GATED RECEPTOR SUPER-FAMILY [J].
SCHOFIELD, PR ;
DARLISON, MG ;
FUJITA, N ;
BURT, DR ;
STEPHENSON, FA ;
RODRIGUEZ, H ;
RHEE, LM ;
RAMACHANDRAN, J ;
REALE, V ;
GLENCORSE, TA ;
SEEBURG, PH ;
BARNARD, EA .
NATURE, 1987, 328 (6127) :221-227
[30]  
SIEGHART W, 1995, PHARMACOL REV, V47, P181